Pictet Asset Management
ENTA icon

Pictet Asset Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Pictet Asset Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-521,311
Closed -$5.82M – 1974
2023
Q3 		$5.82M Buy
+521,311
New +$8.4M 0.01% 749

Other funds holding ENTA

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Pictet Asset Management's ENTA Position: Q4 2023 in Review

Pictet Asset Management sold out of Enanta Pharmaceuticals (ENTA) in Q4 2023, closing a stake of 521,311 shares — an estimated $5.82M sold.

Pictet Asset Management first reported a position in ENTA in Q3 2023 and held it in 1 quarter. The position peaked at $5.82M in Q3 2023. 105 funds tracked by Wall St. Rank hold ENTA as of Q4 2023.

  • Pictet Asset Management reported no remaining Enanta Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Pictet Asset Management sold 521,311 Enanta Pharmaceuticals shares in Q4 2023, an estimated $5.82M.
  • Pictet Asset Management first reported a position in Enanta Pharmaceuticals in Q3 2023 and held it in 1 quarter.
  • Pictet Asset Management's Enanta Pharmaceuticals position peaked at $5.82M in Q3 2023.
  • 105 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2023.

Based on Pictet Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.